<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37748518</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-9064</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Seminars in thrombosis and hemostasis</Title><ISOAbbreviation>Semin Thromb Hemost</ISOAbbreviation></Journal><ArticleTitle>What Role Does Microthrombosis Play in Long COVID?</ArticleTitle><Pagination><StartPage>527</StartPage><EndPage>536</EndPage><MedlinePgn>527-536</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0043-1774795</ELocationID><Abstract><AbstractText>Soon after the outbreak of coronavirus disease 2019 (COVID-19), unexplained sustained fatigue, cognitive disturbance, and muscle ache/weakness were reported in patients who had recovered from acute COVID-19 infection. This abnormal condition has been recognized as "long COVID (postacute sequelae of COVID-19 [PASC])" with a prevalence estimated to be from 10 to 20% of convalescent patients. Although the pathophysiology of PASC has been studied, the exact mechanism remains obscure. Microclots in circulation can represent one of the possible causes of PASC. Although hypercoagulability and thrombosis are critical mechanisms of acute COVID-19, recent studies have reported that thromboinflammation continues in some patients, even after the virus has cleared. Viral spike proteins and RNA can be detected months after patients have recovered, findings that may be responsible for persistent thromboinflammation and the development of microclots. Despite this theory, long-term results of anticoagulation, antiplatelet therapy, and vascular endothelial protection are inconsistent, and could not always show beneficial treatment effects. In summary, PASC reflects a heterogeneous condition, and microclots cannot explain all the presenting symptoms. After clarification of the pathomechanisms of each symptom, a symptom- or biomarker-based stratified approach should be considered for future studies.</AbstractText><CopyrightInformation>Thieme. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iba</LastName><ForeName>Toshiaki</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-0255-4088</Identifier><AffiliationInfo><Affiliation>Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Connors</LastName><ForeName>Jean M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0001-6445-582X</Identifier><AffiliationInfo><Affiliation>Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Jerrold H</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0003-3766-4962</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, Critical Care, and Surgery, Duke University School of Medicine, Durham, North Carolina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Semin Thromb Hemost</MedlineTA><NlmUniqueID>0431155</NlmUniqueID><ISSNLinking>0094-6176</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090882" MajorTopicYN="N">Thromboinflammation</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>T.I. has participated in advisory boards of Japan Blood Products Organization, Toray Medical, and Asahi Kasei Pharmaceuticals and received a research grant from JIMRO. J.M.C. received personal fees from Bristol Myers Squibb, Pfizer, Abbott, Alnylam, Anthos, Roche, and Sanofi; research funding to the institution from CSL Behring. J.H.L. serves on the Steering Committees for Merck, Octapharma, and Werfen.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>21</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>26</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>25</Day><Hour>19</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37748518</ArticleId><ArticleId IdType="doi">10.1055/s-0043-1774795</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>